Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04175470
Other study ID # BeTo-Ovar
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 29, 2019
Est. completion date December 2024

Study information

Verified date May 2024
Source Vejle Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A recent study at the Department of Oncology, Vejle Hospital (NCT02399592), investigated bevacizumab and tocotrienol in ovarian cancer patients and concurrently monitored the level of methylated HOXA9 circulating tumor DNA (HOXA9 meth-ctDNA) in the blood. The rate of disease control was 70% with better results than other studies using bevacizumab alone. The toxicity was very low and attributed to bevacizumab only. When the study results were worked up they showed that patients with a significant increase of HOXA9 meth-ctDNA after the first cycle of treatment did not benefit from the treatment whereas those with stable or decreasing HOXA9 meth-ctDNA did. Therefore, in the current study patients with a high increase of HOXA9 meth-ctDNA after the first treatment cycle will discontinue treatment, as it is then considered ineffective. The remaining patients may achieve prolonged survival as predicted by their level of HOXA9 meth-ctDNA.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed epithelial ovarian cancer, primary fallopian or primary peritoneal cancer. - Platinum resistant epithelial ovarian cancer treated with at least two different previous chemotherapeutic regimens - Progression on previous treatment. Previous treatment with bevacizumab is allowed. - Measurable disease by the RECIST 1.1 criteria or evaluable by the GCIG CA-125 criteria. - Age = 18 years. - Performance status 0-2. - Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion): - WBC = 3.0 x 10^9/l or neutrophils (ANC) = 1.5 x 10^9/l - Platelet count = 100 x 10^9/l - Hemoglobin = 6 mmol/l - Serum bilirubin < 2.0 x ULN - Serum transaminase = 2.5 x ULN - Serum creatinine = 1.5 ULN - Urine dipstick for protein < 2+. If the dipstick shows protein = 2+, 24 hour urine testing must be performed and show protein contents < 1 g. - Written informed consent Exclusion Criteria: - Other malignant disease within 3 years prior to inclusion in the study, except curatively treated basal cell or squamous cell carcinoma of the skin. - Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation. - Intestinal infiltration or infiltration in major blood vessels at the discretion of the treating physician. - Underlying medical disease not adequately treated (diabetes, cardiac disease). - Uncontrolled hypertension (BP > 150/100 despite antihypertensive treatment). - Surgery including open biopsy, within 4 weeks prior to first dose of bevacizumab. - Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within 6 months before start of treatment. - Clinical significant cardiovascular disease, including: - Myocardial infarction or unstable angina within 6 months before start of treatment - New York Heart Association (NYHA) class = 2 - Poorly controlled cardiac arrhythmia despite medication - Peripheral vascular disease grade = 3 - Allergy to active substance or any of the auxiliary agents - Bleeding tumor - Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory. - Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.

Study Design


Intervention

Drug:
Bevacizumab
10 mg/kg intravenously every three weeks
Dietary Supplement:
Tocotrienol
Capsules, 300 mg orally three times daily

Locations

Country Name City State
Denmark Department of Oncology, Vejle Hospital Vejle

Sponsors (1)

Lead Sponsor Collaborator
Vejle Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival 6 months after enrollment of the last patient
Secondary Overall survival 12 months after enrollment of the last patient
Secondary Response rate as measured by RECIST 1.1 or CA-125 6 months after enrollment of the last patient
Secondary Safety as measured by CTC version 5.0 CTC = National Cancer Institute's Common Toxicity Criteria (NCI-CTC) Every 9 weeks until progression, up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT06014528 - IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT03717610 - Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer N/A
Recruiting NCT03983226 - Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Phase 2
Recruiting NCT05095558 - Microtransplantation for Ovarian Cancer Phase 1/Phase 2
Completed NCT03657966 - DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer Phase 2
Not yet recruiting NCT06102707 - The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients N/A
Terminated NCT03162562 - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Phase 1
Withdrawn NCT04149145 - Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer Phase 1
Completed NCT01332656 - Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel Phase 2
Completed NCT01111903 - A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse Phase 1/Phase 2
Recruiting NCT03734692 - Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer Phase 1/Phase 2
Recruiting NCT03827837 - Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors Phase 2
Not yet recruiting NCT05990192 - SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy Phase 2
Completed NCT01485848 - EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer Phase 2
Completed NCT03681548 - A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. Phase 1
Recruiting NCT04072263 - Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer Phase 1/Phase 2